ClinicalTrials.gg
CompletedNCT01628965Updated Mar 19, 2014Results posted

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

A Phase 2/3 interventional study of SPM 962 in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
18th of 42
143 · median 123
Started
2008
the only one that year
Phase 2/3
2 of 44
none open now
Registered
25th of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 18th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2/3, and was the 25th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • SPM 962
  • rotigotine
  • Parkinson's disease
  • monotherapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the preceding trial 243-07-001 (NCT00537485)

Exclusion criteria

Exclusion Criteria:

  • Subject discontinued from the preceding trial 243-07-001.
  • Subject had a serious adverse event which association with the drug was not ruled out during trial 243-07-001.
  • Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-07-001.
  • Subject had persistent hallucination or delusion during trial 243-07-001.
  • Subject has psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.
  • Subject has orthostatic hypotension or a systolic blood pressure (SBP) \<= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.
  • Subject has a history of epilepsy, convulsion etc. during trial 243-07-001.
  • Subject develops serious abnormality at the baseline.
  • Subject has -interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-07-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
  • Subject has a serum potassium level \< 3.5 mEq/L at the end of the taper period in trial 243-07-001.
  • Subject has a total >= 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at the end of the period in trial 243-07-001.
  • Subject has BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-07-001.
  • Subject who plans pregnancy during the trial.
  • Subject has dementia.
  • Subject is unable to give consent.
  • Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    SPM 962

    SPM 962 transdermal patch

    Drug: SPM 962

Interventions

  • SPM 962 transdermal patch once a daily up to 36.0 mg/day

    Also known as: rotigotine

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters

    Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing. \*decrease in difference between supine and standing systolic blood pressure

    Time frame: Up to 55 weeks after dosing

  2. Skin Irritation Score of the Application Site

    Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis. -: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum

    Time frame: Up to 55 weeks after dosing

Secondary outcomes

  1. Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score

    Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, Up to 54 weeks after dosing

07

Results

Posted Mar 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM 962
Started143
Completed94
Not completed49
Withdrew: Adverse event30
Withdrew: Lack of efficacy7
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1
Withdrew: Discontinuation criteria8

Outcome measures

PrimaryIncidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters

Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing. \*decrease in difference between supine and standing systolic blood pressure

Time frame:
Up to 55 weeks after dosing
Reported as:
Number · participants
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
participantsSPM 962
Any AEs140
Treatment-related AEs122
SAEs18
Severe AEs9
Discontinuation due to AEs30
Severe laboratory abnormality14
≥30 mmHg decrease*1
Treatment-related AE of orthostatic hypotension2
QTcB ≥500 ms1
Weight decrease of 5% or more53
Weight increase of 5% or more22
SecondaryTotal of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score

Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, Up to 54 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score
Scores on a scaleSPM 962
Week 12-9.9 ± 8.7
Week 24-8.3 ± 9.5
Week 52-6.5 ± 10.1
PrimarySkin Irritation Score of the Application Site

Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis. -: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum

Time frame:
Up to 55 weeks after dosing
Reported as:
Number · participants
Skin Irritation Score of the Application Site
participantsSPM 962
-20
±57
+46
++12
+++6
++++1
+++>7

Adverse events

Collected over 54 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM 962—24/143 (16.8%)138/143 (96.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventSPM 962
Spinal Compression FractureInjury, poisoning and procedural complications2/143
DehydrationMetabolism and nutrition disorders2/143
Positional VertigoEar and labyrinth disorders1/143
CataractEye disorders1/143
Gastric Ulcer BleedingGastrointestinal disorders1/143
PyrexiaGeneral disorders1/143
Gallbladder PolypHepatobiliary disorders1/143
PyelonephritisInfections and infestations1/143
Clavicle FractureInjury, poisoning and procedural complications1/143
HypoglycaemiaMetabolism and nutrition disorders1/143
Most frequent other events
Showing 10 of 19
Most frequent other events
EventSPM 962
Application Site ReactionGeneral disorders96/143
NauseaGastrointestinal disorders47/143
NasopharyngitisInfections and infestations26/143
VomitingGastrointestinal disorders22/143
ConstipationGastrointestinal disorders21/143
SomnolencePsychiatric disorders17/143
Back PainMusculoskeletal and connective tissue disorders13/143
InsomniaPsychiatric disorders10/143
DizzinessNervous system disorders8/143
Oedema PeripheralGeneral disorders7/143

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SPM 962
<=18 years0
Between 18 and 65 years58
>=65 years85
Age, Continuous
Age, Continuous(years)SPM 962
Mean65.3 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)SPM 962
Female83
Male60
Region of Enrollment
Region of Enrollment(participants)SPM 962
Japan143
08

Study locations

7 sites
  • Chubu Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2012
First posted
Jun 27, 2012
Start
Jan 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Mar 19, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01628965
Responsible party
Sponsor
First posted
Jun 27, 2012
Start date
Jan 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Mar 19, 2014
Last update
Mar 19, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion